Market Insight: Best practice in investigator relationship management
This article was originally published in Scrip
The concept of a biopharmaceutical company, a medical devices firm or a CRO striving to become recognised by independent clinical trial sites as a "sponsor of choice" was almost unheard of less than a decade ago. Yet, the clinical research landscape has evolved and competition for high-performing sites, particularly in the US, has increased. In response, sponsors are working with sites to increase their productivity and to facilitate better working relationships between the parties. Clearly, the stakes are high: late-stage clinical trial failures or delays translate commercially into shortfalls in forecasted revenues and shorter periods of marketing exclusivity.